NGM NGM Biopharmaceuticals Inc

On June 7, 2023, NGM Biopharmaceuticals, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Open Market Sale Agreement^SM, dated June 5, 2020 (the “Sales Agreement” and together with the Amendment, the “Amended Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock, par value $0.001 per share (the “Common Stock”). In connection with the Amendment, the Company intends to file a new shelf registration statement on Form S-3 (the “New Registration Statement”). The controlling provisions of the Amendment will become effective at the time the Securities and Exchange Commission (the “SEC”) declares the New Registration Statement effective. Following the effectiveness of the New Registration Statement, the Amended Sales Agreement will provide for the issuance and sales of shares of Common Stock having an aggregate offering price of up to $100.0 million through Jefferies, which amount includes any unsold shares of Common Stock previously available for sale under the Sales Agreement prior to the effectiveness of the New Registration Statement (the “Amended Sales Agreement Shares”). Sales of Common Stock, if any, under the Amended Sales Agreement will be made in sales deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The foregoing description of the Amended Sales Agreement is not complete and is qualified in its entirety by reference to the Sales Agreement, a copy of which was filed as Exhibit 1.2 to the Company’s Form S-3 filed with the SEC on June 5, 2020, and the Amendment, which is filed as Exhibit 1.1 hereto, and in each case incorporated herein by reference.